The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes

被引：9

作者：

Sharma, Manish ^{[1
]}

Qureshi, Sofia R. ^{[1
]}

Champlin, Richard E. ^{[1
]}

Popat, Uday ^{[1
]}

Giralt, Sergio ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2010年 / 85卷 / 07期

关键词：

D MULTIPLE-MYELOMA; HUMAN IMMUNOGLOBULINS; CHEMOTHERAPY; THALIDOMIDE; EXPERIENCE; PROTEIN;

D O I：

10.1002/ajh.21740

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IgD myeloma is a rare subtype of myeloma that is associated with an aggressive course, resistance to chemotherapy, and a poor outcome. We identified 17 patients with IgD myeloma, who received a hematopoietic stem cell transplantation (HCT) at our institution between August 1988 and June 2008. Fifteen of these 17 patients underwent an autologous (auto) HCT. Complete responses (CRs) were seen in 6 of 15 (40%) patients; three converted from partial response to CR, two from minimal response to CR, and one from very good partial response to CR. The overall response rate after auto HCT was 86% (13 of 15). Kaplan-Meiers estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 38% and 64%, respectively. Median PFS and OS were 18 and 45 months, respectively. These results were comparable with patients receiving autologous HCT for other Ig subtypes of myeloma. Am. J. Hematol. 85:502-504, 2010. (C) 2010 Wiley-Liss, Inc.

引用

页码：502 / 504

页数：3

共 15 条

[1] IMMUNOGLOBULIN-D MULTIPLE-MYELOMA - PRESENTING FEATURES, RESPONSE TO THERAPY, AND SURVIVAL IN A SERIES OF 53 CASES [J].

BLADE, J ;

LUST, JA ;

KYLE, RA .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2398-2404

[2] Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience [J].

Chong, Yong Pil ;

Kim, Shin ;

Ko, Ok Bae ;

Koo, Ja Eun ;

Lee, Danbi ;

Park, Sang Hyoung ;

Park, Soo Jung ;

Lee, Daeho ;

Kim, Sang We ;

Suh, Cheolwon .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2008, 23 (05) :819-824

[3] PLASMA CELL MYELOMA WITH D-MYELOMA PROTEIN (IGD MYELOMA) [J].

FAHEY, JL ;

CARBONE, PP ;

ROWE, DS ;

BACHMANN, R .

AMERICAN JOURNAL OF MEDICINE, 1968, 45 (03) :373-&

[4] Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis [J].

Hayashi, T ;

Yamaguchi, I ;

Saitoh, H ;

Takagi, M ;

Nonaka, Y ;

Nomura, T .

INTERNAL MEDICINE, 2003, 42 (07) :605-608

[5] IGD MULTIPLE-MYELOMA - REVIEW OF 133 CASES [J].

JANCELEWICZ, Z ;

TAKATSUKI, K ;

SUGAI, S ;

PRUZANSKI, W .

ARCHIVES OF INTERNAL MEDICINE, 1975, 135 (01) :87-93

[6] Immunoglobulin D myeloma - Problems with diagnosing and staging (own experience and literature review) [J].

Kuliszkiewicz-Janus, M ;

Zimny, A ;

Sokolska, V ;

Sas, M ;

Kuliczkowski, K .

LEUKEMIA & LYMPHOMA, 2005, 46 (07) :1029-1037

[7] Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [J].

Kyle, R. A. ;

Rajkumar, S. V. .

LEUKEMIA, 2009, 23 (01) :3-9

[8] IGD MULTIPLE-MYELOMA - A CURE AT 21 YEARS [J].

KYLE, RA .

AMERICAN JOURNAL OF HEMATOLOGY, 1988, 29 (01) :41-43

[9] High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma [J].

Maisnar, V. ;

Hajek, R. ;

Scudla, V. ;

Gregora, E. ;

Buchler, T. ;

Tichy, M. ;

Kotoucek, P. ;

Kafkova, A. ;

Forraiova, L. ;

Minarik, J. ;

Radocha, J. ;

Blaha, V. ;

Maly, J. .

BONE MARROW TRANSPLANTATION, 2008, 41 (01) :51-54

[10] A NEW CLASS OF HUMAN IMMUNOGLOBULINS .I. A UNIQUE MYELOMA PROTEIN [J].

ROWE, DS ;

FAHEY, JL .

JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (01) :171-+

← 1 2 →